Table 1 Patient Characteristics at baseline and 3 months from EGFR-TKI
Characteristics N = 207 (%) | Baseline | 3 months from EGFR-TKI | ||
|---|---|---|---|---|
Overall N = 207 | Oligo-residual n = 66 (%) | Non-Oligo n = 141 (%) | P | |
Median age (range) | 68 (34-88) | 67 (41-87) | 68 (34-88) | 0.478 |
Sex | ||||
 Male | 77 (37) | 22 (33) | 55 (39) | 0.431 |
 Female | 130 (63) | 44 (67) | 86 (61) | |
ECOG-PS | ||||
 0 | 43 (21) | 28 (42) | 34 (24) | 0.021 |
 1 | 128 (62) | 36 (55) | 90 (64) | |
 2 | 26 (12) | 2 (3) | 15 (11) | |
 3 | 10 (5) | 0 | 2 (1) | |
Smoking status | ||||
 Ever | 109 (53) | 34 (52) | 64 (45) | 0.411 |
 Never | 98 (47) | 32 (48) | 77 (55) | |
Histology | ||||
 Adenocarcinoma | 196 (95) | 61 (92) | 135 (96) | 0.321 |
 Non-Adenocarcinoma | 11(5) | 5 (8) | 6 (4) | |
Type of EGFR mutation | ||||
 Del 19 | 124 (60) | 33 (50) | 91 (65) | 0.391 |
 L858R | 73 (35) | 30 (45) | 43 (30) | |
 Other | 10 (5) | 3 (5) | 7 (5) | |
Site of metastatic organs | ||||
 Pleura | 122 (59) | 0 | 92 (65) | < 0.001 |
 Pulmonary | 114 (55) | 17 (26) | 63 (45) | 0.009 |
 Bone | 95 (46) | 12 (18) | 62 (44) | < 0.001 |
 Brain | 71 (34) | 6 (9) | 32 (23) | 0.018 |
 Liver | 36 (17) | 7 (11) | 30 (21) | 0.062 |
 Adrenal grand | 24 (12) | 5 (8) | 19 (14) | 0.217 |
 Extra-thoracic lymph node | 23 (11) | 4 (6) | 12 (9) | 0.538 |
 Others | 13 (6) | 2 (3) | 10 (7) | 0.244 |
Number of lesions | ||||
 1 | 0 | 17 (8) | 0 |  |
 2 | 0 | 19 (9) | 0 |  |
 3 | 3 (1) | 20 (10) | 0 |  |
 4 | 10 (5) | 10 (5) | 0 |  |
 5 | 5 (3) | 0 | 2 (1) |  |
 6 | 5 (3) | 0 | 0 |  |
 7 | 1 (0) | 0 | 2 (1) |  |
 8 | 3 (1) | 0 | 1 (0) |  |
 9 | 0 | 0 | 0 |  |
 ≥10 | 180 (87) | 0 | 136 (66) |  |
Number of metastatic organs | ||||
 0 | 0 | 15 (22) | 0 |  |
 1 | 63 (31) | 39 (59) | 60 (43) |  |
 2 | 62 (30) | 11 (17) | 33 (23) | |
 3 | 46 (22) | 1 (2) | 20 (14) | |
 4 | 24 (12) | 0 | 20 (14) | |
 5 | 5 (2) | 0 | 3 (2) | |
 6 | 7 (3) | 0 | 5 (4) | |
EGFR-TKI treatment | ||||
 Gefitinib | 96 (46) | 30 (45) | 66 (47) | 0.132 |
 Erlotinib | 49 (24) | 11 (17) | 38 (27) | |
 Afatinib | 24 (12) | 8 (22) | 16 (11) | |
 Osimertinib | 38 (18) | 17 (26) | 21 (15) | |